News

The Subject Expert Committee (SEC) functional under the Central Drug Standard Control Organisation (CDSCO) has granted ...
Summit Therapeutics Inc. (NASDAQ:SMMT) is one of the best hot stocks to buy according to Wall Street analysts.
Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...
AstraZeneca PLC logged a -2.4% change during today's morning session, and is now trading at a price of $69.45 per share. The ...
(Alliance News) - AstraZeneca PLC on Friday said Imfinzi is "poised to transform the standard of care" as it reported the bladder cancer treatment cleared a European regulatory milestone.
AstraZeneca PLC closed 22.80% short of its 52-week high of £133.88, which the company reached on September 3rd.
By integrating foundation models into its R&D pipeline, AstraZeneca seeks to enable data-driven discovery methods.
Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...
The Cambridge, England-based pharmaceutical company said Imfinzi has been approved in the EU for treatments in adults with resectable muscle-invasive bladder cancer.
It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...
The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.
Shares of Summit Therapeutics jumped 9% Thursday on a report that it was discussing a lucrative partnership deal with AstraZeneca.